An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells

European Journal of Pharmacology

Volumn 600, Issue 1-3, 2008, Pages 37-44

  Chang, Gee Chen ^a,b,c   Yu, Chang Tze Ricky ^d   Tsai, Ching Hwa ^e   Tsai, Jia Rong ^a   Chen, Jen Chi ^e   Wu, Chun Chi ^a   Wu, Wen Jun ^e   Hsu, Shih Lan ^a,e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL CHI NAN UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Gefitinib; p53; shRNA

Indexed keywords

GEFITINIB; PROTEIN P53; PUMA PROTEIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CELL LINE A549; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; UPREGULATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PHOSPHORYLATION; QUINAZOLINES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 55949098667     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.024     Document Type: Article

References (69)

1. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., LoRusso P., Rischin D., Sauleda S., Gee J., Nicholson R.I., and Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20 (2002) 110-124
2. Amantana A., London C.A., Iversen P.L., and Devi G.R. -linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol. Cancer Ther. 3 (2004) 699-707
3. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3 (1997) 917-921
4. Ariyama H., Qin B., Baba E., Tanaka R., Mitsugi K., Harada M., and Nakano S. Gefitinib, a selective EGF receptor tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells. J. Cell Biochem. 97 (2006) 724-734
5. Azzariti A., Xu J.M., Porcelli L., and Paradiso A. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem. Pharmacol. 68 (2004) 135-144
6. Birnbaum A., and Ready N. Gefitinib therapy for non-small cell lung cancer. Curr. Treat Options Oncol. 6 (2005) 75-81
7. Blanc-Brude O.P., Yu J., Simosa H., Conte M.S., Sessa W.C., and Altieri D.C. Inhibitor of apoptosis protein survivin regulates vascular injury. Nature Med. 8 (2002) 987-994
8. Burdak-Rothkamm S., Rube C.E., Nguyen T.P., Ludwig D., Feldmann K., Wiegel T., and Rube C. Radiosensitivity of tumor cell lines after pretreatment with the EGF receptor tyrosine kinase inhibitor ZD1839 (Iressa). Strahlenther. Onkol. 181 (2005) 197-204
9. Campiglio M., Locatelli A., Olgiati C., Normanno N., Somenzi G., Vigano L., Fumagalli M., Menard S., and Gianni L. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J. Cell Physiol. 198 (2004) 259-268
10. Cappuzzo F., Finocchiaro G., Metro G., Bartolini S., Magrini E., Cancellieri A., Trisolini R., Castaldini L., Tallini G., and Crino L. Clinical experience with gefitinib: an update. Crit. Rev. Oncol. Hematol. 58 (2006) 31-45
11. Chang G.C., Hsu S.L., Tsai J.R., Liang F.P., Lin S.Y., Sheu G.T., and Chen C.Y. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells. Biochem. Pharmacol. 68 (2004) 1453-1464
12. Chawla-Sarkar M., Bae S.I., Reu F.J., Jacobs B.S., Lindner D.J., and Borden E.C. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 11 (2004) 915-923
13. Chipuk J.E., Bouchier-Hayes L., Kuwana T., Newmeyer D.D., and Green D.R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309 (2005) 1732-1735
14. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., Bianco A.R., and Tortora G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6 (2000) 2053-2063
15. Daneshmand M., Parolin D.A., Hirte H.W., Major P., Goss G., Stewart D., Batist G., Miller Jr. W.H., Matthews S., Seymour L., and Lorimer I.A. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin. Cancer Res. 9 (2003) 2457-2464
16. Dawson N.A., Guo C., Zak R., Dorsey B., Smoot J., Wong J., and Hussain A. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin. Cancer Res. 10 (2004) 7812-7819
17. Debernardis D., Sire E.G., De Feudis P., Vikhanskaya F., Valenti M., Russo P., Parodi S., D'Incalci M., and Broggini M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res. 57 (1997) 870-874
18. Deveraux Q.L., Takahashi R., Salvesen G.S., and Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388 (1997) 300-304
19. Drucker B., Bacik J., Ginsberg M., Marion S., Russo P., Mazumdar M., and Motzer R. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest. New Drugs 21 (2003) 341-345
20. Fan S., Smith M.L., Rivet II D.J., Duba D., Zhan Q., Kohn K.W., Fornace Jr. A.J., and O'Connor P.M. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55 (1995) 1649-1654
21. Frampton J.E., and Easthope S.E. Spotlight on gefitinib in non-small-cell lung cancer. Am. J. Pharmacogenomics 5 (2005) 133-136
22. Fraser M., Leung B.M., Yan X., Dan H.C., Cheng J.Q., and Tsang B.K. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 63 (2003) 7081-7088
23. Fridman J.S., and Lowe S.W. Control of apoptosis by p53. Oncogene 22 (2003) 9030-9040
24. Freeman B.B., Daw N.C., Geyer J.R., Furman W.L., and Stewart C.F. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest. 24 (2006) 310-317
25. Gee J.M., Harper M.E., Hutcheson I.R., Madden T.A., Barrow D., Knowlden J.M., McClelland R.A., Jordan N., Wakeling A.E., and Nicholson R.I. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144 (2003) 5105-5117
26. Gupta M., Fan S., Zhan Q., Kohn K.W., O'Connor P.M., and Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin. Cancer Res. 3 (1997) 1653-1660
27. Hoffman W.H., Biade S., Zilfou J.T., Chen J., and Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277 (2002) 3247-3257
28. Hollstein M., Rice K., Greenblatt M.S., Soussi T., Fuchs R., Sørlie T., Hovig E., Smith-Sørensen B., Montesano R., and Harris C.C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22 (1994) 3551-3555
29. Hopfner M., Sutter A.P., Gerst B., Zeitz M., and Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br. J. Cancer 89 (2003) 1766-1775
30. Hueber A.O. CD95: more than just a death factor?. Nat. Cell Biol. 2 (2000) E23-25
31. Johnston J.B., Navaratnam S., Pitz M.W., Maniate J.M., Wiechec E., Baust H., Gingerich J., Skliris G.P., Murphy L.C., and Los M. Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem. 13 (2006) 3483-3492
32. Kirsch D.G., and Kastan M.B. Tumor-suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol. 16 (1998) 3158-3168
33. Lambert P.F., Kashanchi F., Radonovich M.F., Shiekhattar R., and Brady J.N. J. Biol. Chem. 273 (1998) 33048-33053
34. Mackenzie M.J., Hirte H.W., Glenwood G., Jean M., Goel R., Major P.P., Miller Jr. W.H., Panasci L., Lorimer I.A., Batist G., Matthews S., Douglas L., and Seymour L. A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest. New Drugs. 23 (2005) 165-170
35. Maecker H.L., Koumenis C., and Giaccia A.J. p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Res. 60 (2000) 4638-4644
36. Magne N., Fischel J.L., Dubreuil A., Formento P., Poupon M.F., Laurent-Puig P., and Milano G. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br. J. Cancer. 86 (2002) 1518-1523
37. Mannick J.B., Hausladen A., Liu L., Hess D.T., Zeng M., Miao Q.X., Kane L.S., Gow A.J., and Stamler J.S. Fas-induced caspase denitrosylation. Science 284 (1999) 651-654
38. Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I., and Reed J.C. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 22 (2003) 2729-2740
39. Mimeault M., Jouy N., Depreux P., and Henichart J.P. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines. Prostate 62 (2005) 187-199
40. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., and Reed J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9 (1994) 1799-1805
41. Mirza A., McGuirk M., Hockenberry T.N., Wu Q., Ashar H., Black S., Wen S.F., Wang L., Kirschmeier P., Bishop W.R., Nielsen L.L., Pickett C.B., and Liu S. Human surviving is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21 (2002) 2613-2622
42. Mohapatra S., Chu B., Zhao X., and Pledger W.J. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res. 65 (2005) 7717-7723
43. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S.L., Galle P.R., Stremmel W., Oren M., and Krammer P.H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188 (1998) 2033-2045
44. Nakagawa K., Tamura T., Negoro S., Kudoh S., Yamamoto N., Yamamoto N., Takeda K., Swaisland H., Nakatani I., Hirose M., Dong R.P., and Fukuoka M. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. 14 (2003) 922-930
45. Nakano K., and Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Molec. Cell. 7 (2001) 683-694
46. O'Connor P.M., Jackman J., Bae I., Myers T.G., Fan S., Mutoh M., Scudiero D.A., Monks A., Sausville E.A., Weinstein J.N., Friend S., Fornace Jr. A.J., and Kohn K.W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57 (1997) 4285-4300
47. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., and Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (2000) 1053-1058
48. Ogino S., Meyerhardt J.A., Cantor M., Brahmandam M., Clark J.W., Namgyal C., Kawasaki T., Kinsella K., Michelini A.L., Enzinger P.C., Kulke M.H., Ryan D.P., Loda M., and Fuchs C.S. Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. Clin. Cancer Res. 11 (2005) 6650-6656
49. Park J.K., Lee S.H., Kang J.H., Nishio K., Saijo N., and Kuh H.J. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells. Anticancer Drugs 15 (2004) 809-818
50. Piechocki M.P., Yoo G.H., Dibbley S.K., Amjad E.H., and Lonardo F. Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu. Int. J. Cancer. 119 (2006) 441-454
51. Price N., and Belani C. Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial. Clin. Lung Cancer. 6 (2005) 214-216
52. Reck M., and Gatzemeier U. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer. Respir. Med. 99 (2005) 298-307
53. Rho J.K., Choi Y.J., Ryoo B.Y., Na I.I., Yang S.H., Kim C.H., and Lee J.C. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer. Cancer Res. 67 (2007) 1163-1169
54. Sax J.K., Fei P., Murphy M.E., Bernhard E., Korsmeyer S.J., and El-Deiry W.S. BID regulation by p53 contributes to chemosensitivity. Nat. Cell Biol. 4 (2002) 842-849
55. Shrader M., Pino M.S., Lashinger L., Bar-Eli M., Adam L., Dinney C.P., and McConkey D.J. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of Akt-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 67 (2007) 1430-1435
56. Sirotnak F.M., Zakowski M.F., Miller V.A., Scher H.I., and Kris M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6 (2000) 4885-4892
57. Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki E., Chai J., Lee R.A., Robbins P.D., Fernandes-Alnemri T., Shi Y., and Alnemri E.S. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410 (2001) 112-126
58. Tong Q.S., Zheng L.D., Wang L., Zeng F.Q., Chen F.M., Dong J.H., and Lu G.C. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther. 12 (2005) 509-514
59. Tullo A.B., Esmaeli B., Murray P.I., Bristow E., Forsythe B.J., and Faulkner K. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye 19 (2005) 729-738
60. Vicentini C., Festuccia C., Gravina G.L., Angelucci A., Marronaro A., and Bologna M. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J. Cancer Res. Clin. Oncol. 129 (2003) 165-174
61. Villunger A., Michalak E.M., Coultas L., Müllauer F., Böck G., Ausserlechner M.J., Adams J.M., and Strasser A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302 (2003) 1036-1038
62. Von-Pawel J. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull. Cancer. 91 (2004) E70-76
63. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., and Gibson K.H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62 (2002) 5749-5754
64. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 82 (1999) 241-250
65. Xu J.M., Azzariti A., Colucci G., and Paradiso A. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. Cancer Chemother. Pharmacol. 52 (2003) 442-448
66. Yamaguchi Y., Shiraki K., Fuke H., Inoue T., Miyashita K., Yamanaka Y., Saitou Y., Sugimoto K., and Nakano T. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol. Rep. 14 (2005) 1311-1316
67. Yu J., Zhang L., Hwang P.M., Kinzler K.W., and Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell. 7 (2001) 673-682
68. Zanchi C., Zuco V., Lanzi C., Supino R., and Zunino F. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. Cancer Res. 65 (2005) 2364-2372
69. Zhou M., Gu L., Li F., Zhu Y., Woods W.G., and Findley H.W. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J. Pharmacol. Exp. Ther. 303 (2002) 124-131